Neuromuscular Disorders Clinical Trials
WE ARE ENROLING NOW!
Amyotrophic Lateral Sclerosis (ALS)
COYA-302-CLN-2301 (Subcutaneous Injection)
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Blinded Active Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in adults aged 18-75 years.
Principal Investigator: Sheetal Shroff, MD
Contact: Aramide Balogun | abalogun@houstonmethodist.org | 713.441.6955
Idiopathic Inflammatory Myopathies (IIM)
CAB-2010-002 (CAR-T) RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated. In adults aged 18-75 years.
Principal Investigator: Bing Liao, MD
Contact: Amelia Nounes | aanounes@houstonmethodist.org | 346.356.3639
Myasthenia gravis (MG)
Novartis YTB323 (Biological CAR-T Cells)
A phase 1/2 Open label study intended to assess safety, efficacy, and cellular kinetics of YTB323 in adults aged 18-65 years with treatment- resistant Generalized Myasthenia Gravis.
Principal Investigator: Ericka Greene, MD
Contact: Jennifer Garrett | jmgarrett@houstonmethodist.org | 346.238.4516
RemGen (RC18G006 Telitacicept) prefilled syringe
A Phase 3 Randomized, Double-Blind, placebo-controlled study with an Open-Label Extension to evaluate the efficacy and safety of telitacicept in the treatment of Generalized Myasthenia Gravis in adult participants aged 18 years and older.
Principal Investigator: Bing Liao, MD
Contact: Samia Saad | ssaad@houstonmethodist.org
Novartis CLOU064O12301 A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (RELIEVE)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled study to evaluate efficacy, safety and tolerability of Remibrutinib versus placebo in adult participants aged 18-75 years with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
Principal Investigator: Ericka Greene, MD
Contact: Delrose Vernon | davernon@houstonmethodist.org | 713.441.9484
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults (aged 18 years and olde) with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.
Principal Investigator: Sheetal Shroff, MD
Contact: Aramide Balogun | abalogun@houstonmethodist.org | 713.441.6955
Donate to Houston Methodist
With your support, Houston Methodist provides exceptional research, education, and care that is truly leading medicine.
Donate Now